Carlos Gil Ferreira

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

Adrianus J. de Langen, Melissa L. Johnson, Julien Mazières et al. · The Lancet · 2023 · 566 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Apoptosis: target of cancer therapy.

Carlos Gil Ferreira, Mirjam T. Epping, Frank A.E. Kruyt et al. · PubMed · 2002 · 255 citations

Life Sciences, Cancer Biology, Oncology +17

Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2

Mauro Zukin, Carlos H. Barrios, José Rodrigues Pereira et al. · Journal of Clinical Oncology · 2013 · 238 citations

Medicine, Oncology, Pharmacology +11

IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras–Mutant Lung Cancer

Mauricio S. Caetano, Huiyuan Zhang, Amber M. Cumpian et al. · Cancer Research · 2016 · 220 citations · Full text

Medicine, Cancer Biology, Oncology +17